ArticleThe Journal of infectious diseases2023
The Estimated Lifetime Quality-Adjusted Life-Years Lost Due to Chlamydia, Gonorrhea, and Trichomoniasis in the United States in 2018.
Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.The New England journal of medicine · 2023Trial
- Correlates of Sexually Transmitted Infection Positivity and Implementation of Point-of-Care Sexually Transmitted Infection Testing at a Mobile Clinic for Women Who Inject Drugs in Seattle, WA.Sexually transmitted diseases · 2026Article
- Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: an agent-based model and cost-effectiveness analysis.Lancet regional health. Americas · 2026Article
- Optimal Deployment of Gonorrhoea Point-of-Care Tests: Modeling the Potential Impact of Diagnostic Confirmation Testing and Screening Strategies Across Five Priority Populations in Kenya.The Journal of infectious diseases · 2026Article
- Estimating State-Level Chlamydia and Gonorrhea Incidence and Prevalence Among Women in the United States, 2019-2023: Mathematical Modeling Analysis.Open forum infectious diseases · 2026Article
- Evaluating the potential health and economic impacts of chlamydia vaccination strategies in the United States: a mathematical modeling and cost-effectiveness simulation study.Lancet regional health. Americas · 2026Article
- Antimicrobial resistance crisis in STIs: Gonorrhea andNew microbes and new infections · 2026Review
- Self-Reported Prevalence and Predictors of HIV and Gonorrhea Among Primary Healthcare Attendees: A Cross-Sectional Study from Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Impact and cost-effectiveness of doxycycline post-exposure prophylaxis in Australian men who have sex with men.Nature communications · 2026Article
- Vaginal microbiome and sexually-transmitted pathogens in Chinese reproductive-age women: a multicentre cross-sectional and longitudinal cohort study.Nature communications · 2025Observational
- The economic burden of outpatient chlamydia infections in Southern China: a cross-sectional study, 2021-2023.BMJ open · 2025Article
- The global disease burden attributable to unsafe sex among women from 1990 to 2021 with forecasts to 2035: a systematic analysis based on the global burden of disease 2021.BMC public health · 2025Article
- Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness.NPJ vaccines · 2025Article
- Unveiling the Cost-Effectiveness of Chlamydia Screening Strategies: A Systematic Review.Portuguese journal of public health · 2025Review
- From Cure to Prevention: Doxycycline's Potential in Prophylaxis for Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design.PLoS pathogens · 2024Article
- Seroprevalence of sexually transmitted infections over 44 years - A cross-sectional study in Sweden.International journal of STD & AIDS · 2024Article
- Antimicrobial treatment and resistance in sexually transmitted bacterial infections.Nature reviews. Microbiology · 2024Review
- Challenges and Solutions to STI Control in the Era of HIV and STI Prophylaxis.Current HIV/AIDS reports · 2023Review
- Targeted versus Universally Offered Screening in Pediatric Emergency Departments: Cost-Effectiveness.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundComprehensive evaluation of the quality-adjusted life-years (QALYs) lost attributable to chlamydia, gonorrhea, andtrichomoniasis in the United States is lacking.
methodsWe adapted a previous probability-tree model to estimate the average number of lifetime QALYs lost due to genital chlamydia, gonorrhea, and trichomoniasis, per incident infection and at the population level, by sex and age group. We conducted multivariate sensitivity analyses to address uncertainty around key parameter values.
resultsThe estimated total discounted lifetime QALYs lost for men and women, respectively, due to infections acquired in 2018, were 1541 (95% uncertainty interval [UI], 186-6358) and 111 872 (95% UI, 29 777-267 404) for chlamydia, 989 (95% UI, 127-3720) and 12 112 (95% UI, 2 410-33 895) for gonorrhea, and 386 (95% UI, 30-1851) and 4576 (95% UI, 13-30 355) for trichomoniasis. Total QALYs lost were highest among women aged 15-24 years with chlamydia. QALYs lost estimates were highly sensitive to disutilities (health losses) of infections and sequelae, and to duration of infections and chronic sequelae for chlamydia and gonorrhea in women.
conclusionsThe 3 sexually transmitted infections cause substantial health losses in the United States, particularly gonorrhea and chlamydia among women. The estimates of lifetime QALYs lost per infection help to prioritize prevention policies and inform cost-effectiveness analyses of sexually transmitted infection interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.